In a news release, Revive Therapeutics Ltd. (RVV:TSX.V; RVVTF:OTCMKTS) announced that it got approval from an independent investigational review board to proceed with its expanded access protocol for the compassionate use of Bucillamine, in hospitalized patients with severe COVID-19.
Revive's expanded access program, which is covered by the U.S. Food and Drug Administration's compassionate use provision, gives qualifying patients access to Bucillamine through their physicians.
Participating inpatients will be administered Bucillamine 200 milligrams orally three times a day for up to 14 days and will be monitored during that period for side effects and drug safety and efficacy. Subsequently, a study nurse will conduct two safety assessments with the participants, at 14 and 42 weeks post completion of treatment.
Revive is carrying out this program as a complement to its Phase 3 COVID-19 trial in the U.S., for which enrollment should begin this month.
"The expanded access protocol (EAP) serves as an option for patients that are not eligible for inclusion criteria in our Phase 3 clinical study in COVID-19, and the resulting data from the EAP will be valuable in supporting our clinical development of Bucillamine," Revive CEO Michael Frank explained in the release.
Read what other experts are saying about:
Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Revive Therapeutics. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Revive Therapeutics, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
